Having taken the preparation steps proven to reduce risk and increase long-term success, you now have a suite of market-leading therapies at your fingertips. You’ll have everything you need to give the best quality of life to your patients.
AGENT IDE Clinical Trial
Results from the first coronary DCB study in the U.S. successfully achieved the primary endpoint at the 1-year mark, revealing favorable rates of adverse events. The AGENT IDE Clinical Trial further substantiated the superiority of AGENT DCB over traditional balloon angioplasty in mitigating target lesion failure for the treatment of coronary ISR.
SYNERGY BP Stents reduce stent thrombosis
In the Kang Meta-Analysis, SYNERGY was ranked #1 for lowest relative risk of definite/probably stent thrombosis at one year, when compared to other stents in the industry. In the SCAAR Registry, the SYNERGY BP Stent had the lowest rate of stent thrombosis at one year compared to other new generation DES, despite being used in statistically more complex patients.
Proven excellent outcomes with short DAPT
SYNERGY BP stents are intentionally designed with thin struts and a fast absorbing, abluminal polymer to enable short DAPT. SYNERGY has been studied with various DAPT durations in a variety of patient populations. The EVOLVE Short DAPT Trial showed that the SYNERGY BP Stent demonstrated low stent thrombosis in the 12 months following 3-month DAPT.
1. Scheller B, Rissanen TT, Farah A, et al. Drug-coated balloon for small coronary artery disease in patients with and without high-bleeding risk in the BASKET-SMALL 2 trial. Circ Cardiovasc Interv. 2022;15:e011569.